Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 1016

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 1016
---
 WHEREAS, Section7.4 of the Merger Agreement provides that the Merger Agreement may be amended, modified or supplemented by a duly authorized instrument specifically designated as an amendment to the Merger Agreement and signed on behalf of each of the parties in interest at the time of such amendment; and

C. WHEREAS, Parent, the Company, Merger Subs and the Stockholders Representative desire to amend the Merger Agreement pursuant to Section7.4 thereof to clarify certain terms and provisions thereof.

<div align='center'>**AGREEMENT**</div>

NOW, THEREFORE, in consideration of the mutual agreements, covenants and other promises set forth herein, the mutual benefits to be gained by the performance thereof, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, Parent, Merger Sub and the Company hereby agree as follows:

1. AMENDMENT TO SECTION 6.2(e) OF THE MERGER AGREEMENT. Section6.2(e) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:

“(e) Concurrent Investment. The Concurrent Investment shall have been completed and the receipt of gross proceeds to Parent of not less than Twenty Million Dollars ($20,000,000), which gross proceeds shall have been received by Parent, or will be received by Parent substantially simultaneously with the Closing.”

2. AMENDMENT TO SECTION 6.2(g) OF THE MERGER AGREEMENT. Section6.2(g) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:

“(g) Company Net Working Capital Deficit. The Estimated Net Working Capital Deficit, if any, shall not be greater than Six Million Dollars ($6,000,000).”

3. AMENDMENT TO SECTION 7.1(b)(i) OF THE MERGER AGREEMENT.Section7.1(b)(i) of the Merger Agreement is hereby amended and restated in its entirety as follows:

“(i) the Mergers shall not have been consummated by June 30, 2025 (subject to possible extension as provided in this Section7.1(b)(i), the “End Date”); provided, however, that the right to terminate this Agreement under this Section7.1(b)(i) shall not be available to the Company or Parent if such party’s (or in the case of Parent, Merger Sub I or Merger Sub II) action or failure to